West Pharmaceutical Services (WST) Non-Current Deffered Revenue (2019 - 2026)

West Pharmaceutical Services (WST) has reported Non-Current Deffered Revenue for 8 consecutive years, with $13.9 million the latest figure, recorded in Q2 2026.

• Quarterly Non-Current Deffered Revenue rose 11.2% year-over-year to $13.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.9 million (up 11.2% YoY) and the FY2025 annual result came in at $13.5 million, down 12.34% from the prior year.
• Non-Current Deffered Revenue advanced to $13.9 million in Q2 2026 per WST's latest filing, from $11.8 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for WST reached as high as $26.3 million in Q1 2022 and fell as low as $11.4 million in Q1 2025.
• A 5-year average of $16.9 million and a median of $16.7 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue rose 16.89% — and 2025, when it slumped 38.71%.
• Year by year, Non-Current Deffered Revenue stood at $19.1 million in 2022, then retreated by 2.62% to $18.6 million in 2023, then fell by 17.2% to $15.4 million in 2024, then retreated by 12.34% to $13.5 million in 2025, then increased by 2.96% to $13.9 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $13.9 million, $11.8 million, and $13.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.